Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, today announces that results from ADVANCE, a Phase 1/2 study in metastatic castrate resistant prostate cancer (mCRPC), sponsored by the University of Oxford, will be presented at the European Society for Medical Oncology (ESMO) virtual congress. The results, courtesy of the Jenner Institute, University of Oxford, include safety, T cell immunogenicity and individual PSA responses from 23 mCRPC patients who received VTP-800, a prime-boost immunotherapeutic regimen of ChAdOx and MVA targeting the oncofetal antigen, 5T4, in combination with the anti-PD-1 checkpoint inhibitor, nivolumab.
Format: Poster 682P, Abstract #4172; Results from ADVANCE, a Phase I/II open-label non-randomised safety and efficacy study of the viral vectored
ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer
Presented by Dr. Mark Tuthill
Date: 17th September 2020
To access the poster click here